Last reviewed · How we verify

Dexketoprofen Trometamol + Paracetamol

Yuzuncu Yil University · FDA-approved active Small molecule

Dexketoprofen Trometamol + Paracetamol is a NSAID + analgesic combination Small molecule drug developed by Yuzuncu Yil University. It is currently FDA-approved for Acute pain management, Postoperative pain, Musculoskeletal pain.

Dexketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, while paracetamol acts as an analgesic and antipyretic through central nervous system pathways.

Dexketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, while paracetamol acts as an analgesic and antipyretic through central nervous system pathways. Used for Acute pain management, Postoperative pain, Musculoskeletal pain.

At a glance

Generic nameDexketoprofen Trometamol + Paracetamol
SponsorYuzuncu Yil University
Drug classNSAID + analgesic combination
TargetCOX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Dexketoprofen trometamol is the active S-enantiomer of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, thereby reducing inflammation, pain, and fever. Paracetamol (acetaminophen) complements this action through distinct mechanisms involving central inhibition of prostaglandin synthesis and modulation of pain perception. The combination provides enhanced analgesic and anti-inflammatory effects for acute pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexketoprofen Trometamol + Paracetamol

What is Dexketoprofen Trometamol + Paracetamol?

Dexketoprofen Trometamol + Paracetamol is a NSAID + analgesic combination drug developed by Yuzuncu Yil University, indicated for Acute pain management, Postoperative pain, Musculoskeletal pain.

How does Dexketoprofen Trometamol + Paracetamol work?

Dexketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, while paracetamol acts as an analgesic and antipyretic through central nervous system pathways.

What is Dexketoprofen Trometamol + Paracetamol used for?

Dexketoprofen Trometamol + Paracetamol is indicated for Acute pain management, Postoperative pain, Musculoskeletal pain.

Who makes Dexketoprofen Trometamol + Paracetamol?

Dexketoprofen Trometamol + Paracetamol is developed and marketed by Yuzuncu Yil University (see full Yuzuncu Yil University pipeline at /company/yuzuncu-yil-university).

What drug class is Dexketoprofen Trometamol + Paracetamol in?

Dexketoprofen Trometamol + Paracetamol belongs to the NSAID + analgesic combination class. See all NSAID + analgesic combination drugs at /class/nsaid-analgesic-combination.

What development phase is Dexketoprofen Trometamol + Paracetamol in?

Dexketoprofen Trometamol + Paracetamol is FDA-approved (marketed).

What are the side effects of Dexketoprofen Trometamol + Paracetamol?

Common side effects of Dexketoprofen Trometamol + Paracetamol include Gastrointestinal upset, Dyspepsia, Nausea, Dizziness, Headache.

What does Dexketoprofen Trometamol + Paracetamol target?

Dexketoprofen Trometamol + Paracetamol targets COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol) and is a NSAID + analgesic combination.

Related